ther
kenji
vivo
EP
100
introduce
takeshi
IC50
could
condition
2006
VEGFR
daisuke
IQP
radioactivity
agent
formamidine
trifluoromethanesulfonimide
οnurmaya
group
re
tri
might
dihydrate
preparation
conclusion
115
viability
PDGFRβ
acetic
carbonate
reflux
dibenzylideneacetone
bxpc3
block
HN
general
2360
compound
radiochemical
odani
radiolabeled
derivative
chloride
kiyono
TKI
frontier
using
NH2
IB
university
anhydrate
2005
triethylamine
mouse
benzimidazole
mutation
min
other
value
introduction
drug
institute
easily
puritie
target
hcl
vitro
yasushi
DIPHOS
mobile
TR
high
x103
yamada
inhibitor
5C18
ATE
phenyl
tyrosine
1cancer
tumor
x105
added
nude
yoji
boc
after
C6H5
pharm
respectively
control
precursor
statu
probe
method
2019
stable
study
106
kanazawa
measured
ogawa
family
UV
mscl
PBS
sodium
inoculation
cesium
bromide
PCT1
reagent
chem
nte
rin
radiotracer
temperature
1221
II
2onco
oncology
pocl3
bi
science
235825
useful
well
reaction
IIQP
PDGFRα
kazuhiro
cancer
hexabutyldistannane
chromatogram
2008
dipalladium
1215
promising
acid
absorbance
potassium
without
makino
med
NBS
150
wa
tungstate
yield
PET
log
bearing
column
boronic
NCS
acetate
radiobrominated
B1
prepared
more
takarada
meoh
expressed
palladium
time
instead
001
peroxide
concentration
300
suppl
luc
76br
US
under
brb
water
BINAP
asses
than
kazuma
stability
meaningful
patent
overnight
radiolabeling
density
european
77br
ID
quinoline
dose
1000
reference
mishiro
into
evaluation
cell
purity
therapy
966
development
uptake
WST
incubation
TFA
imaging
kitamura
optical
receptor
ing
used
EGFR
kinase
mice
MCF7
non
partition
effendi
rac
957
sacrifice
carrier
tool
bromodestannylation
365
shiba
HPLC
125I
initiative
TEA
phase
000
briqp
sensitivity
tin
benzyl
specification
synthesi
DMSO
akira
counter
studie
MS
normal
biodistribution
blocking
coefficient
february
2014
37oc
strategy
flow
evaluate
bromosuccinimide
protein
rate
result
hydrogen
test
formic